NCT04291092

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Camrelizumab Combined With Chemotherapy and Local Treatment in Non-small Cell Lung Cancer Patients With Brain Metastasis, a Single-arm, Multi-center, Open-labeled Phase II Clinical Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 63 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment in non-small cell lung cancer with brain metastases.

Detailed description

To evaluate the efficacy and safety of Camrelizumab Combined with Chemotherapy and Local Treatment of brain metastases (WBRT, r-knife, SRS, etc.) in non-small cell lung cancer patients with brain metastases .

Conditions

• NSCLC Stage IV
• Brain Metastases
• Immunotherapy

Interventions

Type	Name	Description
DRUG	Immunotherapy	Immunotherapy for brain metastasis
RADIATION	WBRT	local therapy for brain metastasis
DRUG	Chemotherapy	Chemotherapy for brain metastasis

Timeline

• Start date: 2020-01-01
• Primary completion: 2022-06-30
• Completion: 2023-06-30
• First posted: 2020-03-02
• Last updated: 2021-09-10

Locations

1 site across 1 country: China